© 2020 MJH Life Sciences and Urology Times. All rights reserved.
© 2020 MJH Life Sciences™ and Urology Times. All rights reserved.
July 14, 2020
72.9% of patients with papillary disease achieved high-grade recurrence-free survival at 3 months after initial treatment.
June 29, 2020
The deletion of code 99201 is among the evaluation/management coding changes for 2021.
July 09, 2020
3 urologists discuss their experience with telemedicine during the COVID-19 pandemic.
July 03, 2020
The decline in total testosterone was observed even among men with normal body mass index.
Significant improvements in BPH-related lower urinary tract symptoms were observed with the system.
June 30, 2020
The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.
July 28, 2020
"This new therapy could change the landscape for the treatment of advanced prostate cancer," Thrasher writes.
June 23, 2020
Only 1.5% of patients undergo repeat surgical intervention for BPH recurrence.
July 27, 2020
Oral GnRH receptor antagonist has “potential to become a new standard for ADT,” a study investigator says.
July 07, 2020
Samuel J. Peretsman, MD, discusses which patients with prostate cancer can be treated with HIFU, contraindications to the treatment, and what expectations patients need to have postoperatively.
July 15, 2020
The study compared regimens for patients with high-risk non–muscle invasive bladder cancer.
July 08, 2020
Withdrawals from pretax retirement accounts are among the ways to bridge your income, according to Jeff Witz, CFP.
Dr. Badar M. Mian highlights the safety and efficacy of relugolix, describing the drug as an “exciting new option” for patients with recurrent or advanced prostate cancer.